Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Journal Volume
126
Date Issued
2023-01
Author(s)
Tsai, Mao-Song
Chen, Cheng-Pin
Lee, Chen-Hsiang
Lee, Chun-Yuan
Liu, Chun-Eng
Tang, Hung-Jen
Hung, Tung-Che
Li, Chia-Wen
Lee, Yuan-Ti
Liou, Bo-Huang
Yang, Chia-Jui
Abstract
Real-world experience with coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) is sparse as a switch regimen among people living with HIV (PLWH) having achieved viral suppression after previous virologic failures with the emergence of K65N/R.
Subjects
Genetic barrier; Integrase strand-transfer inhibitor; Low-level viremia; Nucleoside reverse-transcriptase inhibitor; Resistance-associated mutation; Viral rebound
Type
journal article